Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FFSX gettin purdy
CRBC is at .78 was over 20.00 in 2008.
GFG .17 Guaranty Financial Group Inc book value over $20 a share.
OPXA News
Opexa's Stem Cell Therapy for Diabetes Shows Progress
Date : 03/17/2009 @ 7:30AM
Source : Business Wire
Stock : Opexa Therapeutics, Inc. (OPXA)
Quote : 0.3 -0.08 (-21.05%) @ 8:00PM
Opexa's Stem Cell Therapy for Diabetes Shows Progress
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company dedicated to the development of stem cell therapies for diabetes today announced new preclinical data to support its autologous stem cell therapy program. Opexa completed confirmatory studies within its c-GMP facility showing that cells obtained from peripheral blood have the ability to differentiate into stem cells and ultimately into pancreatic-like cells. Opexa’s proprietary technology has shown that peripheral blood mononuclear cells obtained from the blood of healthy and diabetic patients can differentiate into pancreatic islet-like cells, demonstrating many of the expected characteristics of true pancreatic islet cells including the ability to secrete insulin, glucagon and somatostatin. Additional studies recently completed by Opexa’s scientists also support these findings showing high levels of C-peptide, a by-product of insulin synthesis, within these islet-like cells, as well as many key stem cell and pancreatic biomarkers.
Opexa is currently completing preclinical development and advancing toward a Phase I clinical trial for the use of its proprietary autologous stem cell therapy derived from a patient’s own blood for the treatment of diabetes. Preclinical data obtained in animal and in vitro studies to date have been encouraging and have yielded the following results:
Opexa has derived multipotent stem cells from peripheral blood mononuclear cells obtained from the blood of both healthy and diabetic subjects. These stem cells have been differentiated into insulin-producing islet-like clusters.
These islet-like clusters express a variety of endocrine specific markers, are composed of the key pancreatic cell types (α, β, δ), and are able to synthesize and secrete insulin in a glucose-responsive manner in vitro.
In vivo studies involving the subcapsular kidney transplantation of these islet-like clusters into diabetic NOD/SCID mice resulted in a reduction in the blood glucose levels for prolonged periods of time.
Additional preclinical studies are planned to examine optimal dosing, delivery and route of administration of the islet-like clusters, and toxicology. Following a preliminary meeting with the FDA and through consultations with its Clinical Advisory Board, Opexa has designed a Phase I clinical study protocol. Primary endpoints are proposed to be safety of monocyte derived pancreatic-like islet cell transplantation and insulin independence or reduction in exogenous insulin requirements at one year post initial infusion.
“I am pleased to see important advances with our stem cell therapy as this technology could offer benefits not only for the treatment of diabetes but also in other disease areas,” remarked Neil K. Warma, president and chief executive officer. “We are also hopeful to be able to derive one course of treatment from a single blood draw from a diabetic patient which, ideally, would lead to a readily available source of patient-specific β-cells suitable for autologous cell transplantation.”
“We have developed a manufacturing process based on a small-scale, bag-based system which we believe should yield significant cost savings over typical embryonic stem cell and cadaveric cell manufacturing processes,” commented Donna Rill, senior vice president, Operations. “We have extensive experience with cell therapy technology having just completed a 150 patient Phase IIb clinical study with our T-cell therapy and have applied many of the same principles to our stem cell manufacturing process. Much work still remains but we are encouraged with these data.”
About Opexa
Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product is Tovaxin, a T-cell therapy for multiple sclerosis that recently completed Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte-derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for diabetes mellitus. For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com
RODM Chart:
PIR Chart:
PANC Chart:
APII Chart:
CWST +43%
CSAR +75%
ANSV +12% .30, high was .42
thanks TM
nice charts IB
MECA Chart:
CWST Chart:
CSAR Chart:
NYSE considers relaxing minimum share price rule
http://finance.yahoo.com/tech-ticker/article/192663/The-Stock-Market-Is-Signaling-Things-Are-Better-Than-You-Think?tickers=%5Edji,%5Egspc,%5EVIX,XLF,SPY,DIA,QQQQ
GKK @ .73 52 week high is over $20 a share. Book value over $18 Can you say way, way over sold.
MESA >MESA AIR GROUP, INC. (Nasdaq: MESA) (the "Company") announced today that is has entered into separate agreements with certain holders of its Senior Convertible Notes due 2024 (the "2024 Notes") to exchange $83.7 million in aggregate principal amount at maturity of the 2024 Notes for an aggregate of $4.9 million in cash, 10.9 million shares of the Company's common stock, no par value (the "Common Stock"), and $16.3 million in aggregate principal amount of the Company's new 8% senior unsecured notes due 2012 (the "2012 Notes"). The issuance of the Common Stock and 2012 Notes in the exchange, which is expected to close on or about February 25, 2009, is exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 3(a)(9) and Section 4(2) thereof. These new agreements have terms that are substantially similar to former agreements with the same holders of 2024 Notes that were previously rescinded.
(Logo: http://www.newscom.com/cgi-bin/prnh/19990210/LAW065)
The execution of the above exchange agreements follows the previously announced transactions summarized below and concludes the Company's repurchase obligations under the Indentures governing the Senior Convertible Notes due 2023 (the "2023 Notes") and 2024 Notes and the Company's efforts to effectuate an overall restructuring such Notes:
*During the first two weeks of February 2009, the Company (i) issued 3,434,000 shares of its Common Stock in satisfaction of its obligation to repurchase $1.4 million in aggregate principal amount at maturity of its 2023 Notes from holders of 2023 Notes that had exercised their put rights arising under the indenture governing the 2023 Notes and forbearance agreements between the Company and certain of these holders, and (ii) completed transactions with certain holders of its 2023 Notes to purchase an additional $29,071,250 face amount of 2023 Notes and waive the January 31, 2009 put rights for $15,600,000 face amount of 2023 Notes in exchange for a total of $1,844,431 in cash, 8,430,457 shares of its Common Stock and $1.0 million in aggregate principal amount of the 2012 Notes.
*Also during February 2009, the Company repurchased $19,278,000 in aggregate principal amount at maturity of its 2024 Notes from holders of 2024 Notes that had exercised their put rights arising under the indenture governing the 2024 Notes, including $6,504,000 in aggregate principal amount at maturity of 2024 Notes pursuant to certain puts the Company agreed to accept following the initial put period. In consideration for the $19,278,000 in face value of the 2024 Notes, the Company issued 94,269,420 shares of its Common Stock.
Following the closing of the aforementioned exchange transactions and after giving effect to the 2023 Notes and 2024 Notes that were previously acquired by the Company, $21.7 million in aggregate principal amount at maturity of the 2023 Notes and $17.4 million in aggregate principal amount at maturity of the 2024 Notes will remain outstanding. The outstanding 2023 Notes and 2024 Notes may be put to the Company no earlier than June 16, 2013 and February 10, 2014, respectively, under the terms of the Indenture governing such Notes.
The below table summarizes the Company's outstanding convertible notes and outstanding shares before and after the disclosed transactions.
Prior to After All Transactions
Transaction Effective 2/25/09
Face Face Cash Shares
Amount Amount Paid by Issued by
Outstanding Outstanding Mesa Mesa
Senior Notes due $52.1M $21.7M $1.9M 11,864,457
June 2023
Senior Notes due $120.4M $17.4M $4.9M 105,208,170
Feb 2024
New Notes due 0 $17.2M - -
2012
Total $172.5M $56.3M $6.8M 117,072,627
Prior to After All Transactions
Transaction Effective 2/25/09
Total Shares
Outstanding 29,618,160 146,690,787
"We are pleased to have re-established agreements to retire $83.7 million of our 2024 Notes on terms that we believe are favorable to all parties involved and to have completed the restructuring of our 2023 Notes and 2024 Notes. The restructuring of these Notes, together with our return to profitability in the first quarter of fiscal 2009, are critical accomplishments to the long term health and ongoing profitability of the Company," said Jonathan Ornstein, Chairman and CEO of Mesa Air Group, Inc.
This press release contains various forward-looking statements that are based on management's beliefs, as well as assumptions made by and information currently available to management. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable; it can give no assurance that such expectations will prove to have been correct. Such statements are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated, projected or expected.
Mesa currently operates 151 aircraft with over 800 daily system departures to 124 cities, 38 states, the District of Columbia, Canada, the Bahamas and Mexico. Mesa operates as Delta Connection, US Airways Express and United Express under contractual agreements with Delta Air Lines, US Airways and United Airlines, respectively, and independently as Mesa Airlines and go!. In June 2006 Mesa launched inter-island Hawaiian service as go!. This operation links Honolulu to the neighbor island airports of Hilo, Kahului, Kona and Lihue. The Company, founded by Larry and Janie Risley in New Mexico in 1982, has approximately 5,000 employees and was awarded Regional Airline of the Year by Air Transport World magazine in 1992 and 2005.
Website: www.mesa-air.com
SOURCE Mesa Air Group, Inc.
ANX Chart:
ANX..chart please
I hope it busts that 20DMA right out of the gate tomorrow..
Nice chart...
IPT Chart: Looking better...
IBAS Chart:
IPT -- been accumulating IPT .06 - .08 for tiny position high-risk gamble swing trade.
Q4 seasonally strongest and always reports huge EPS and sometimes gives the stock a big pop....earnings are due at the end of the month and the EPS figure for Q4 based on historical periods will be bigger than the current price per share! They tend to make all of their money in Q4 being a party retailer so it's a POS for sure the rest of the year, but at .06-.08 it seems like a decent gamble for a possible double to quadruple with penny listed stocks getting some big pops lately. Tiny penny AMEX/NYSE/NASDAQ stocks are looking for reasons to run. I just think a huge EPS report may give it the catalyst/excuse to just run. They reported .12 EPS last year and sales looking possibly better for this year. A .08 could pop really hard with a .12+ EPS announcement.
Q4 Potential from the November PR:
"For the five week fiscal month of October, which ended on November 1 st , sales at comparable stores increased 1.1% compared to fiscal October 2007. Total company sales increased by 3.9% for the fiscal month compared to the same period in 2007. The increase in total company sales for the calendar and fiscal months of October included the impact of two stores opened and two stores closed in January 2008, as well as the impact of two temporary Halloween stores opened in mid-September 2008."
MPET Chart:
MESA Chart:
FSNM Chart:
EGLS Chart:
CORS Chart:
CNXT Chart:
CHTR Chart:
AVZA Chart:
ATSG Chart:
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
388
|
Created
|
01/11/09
|
Type
|
Free
|
Moderators |
This board will be for NASDAQ - AMEX - NYSE stock plays Under A Buck ONLY!!
[chart]www.lessthanonebuck.com/images/less_than_one_buck_big.gif[/chart]
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |